Highlights Keros Therapeutics, Inc.

Equities

KROS

US4923271013

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-22 pm EDT			5-day change	1st Jan Change
51.11 ^USD	+1.35%		-6.05%	+28.55%

May. 08	Earnings Flash (KROS) KEROS THERAPEUTICS Reports Q1 Revenue $83,000	MT
May. 08	Keros Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Earnings Flash (KROS) KEROS THERAPEUTICS Reports Q1 Revenue $83,000	May. 08	MT
Keros Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 08	CI
Keros Therapeutics Shares Rise After FDA Fast Track Designation for Potential Anemia Drug	Mar. 15	MT
Keros Therapeutics Gets FDA Fast Track Designation for Anemia Drug	Mar. 14	MT
Keros Therapeutics Announces U.S. FDA Fast Track Designation for KER-050 in Lower-Risk Myelodysplastic Syndromes	Mar. 14	CI
Keros Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 28	CI
Keros Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Feb. 28	CI
Earnings Flash (KROS) KEROS THERAPEUTICS Reports Q4 Revenue $143,000	Feb. 28	MT
Keros Therapeutics, Inc. to Develop KER-065 for the Treatment of Obesity	Jan. 03	CI
Keros Therapeutics, Inc. Presents Clinical Data from its KER-050 Program at the 65th American Society of Hematology Annual Meeting and Exposition	Dec. 11	CI
Keros Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 06	CI
Earnings Flash (KROS) KEROS THERAPEUTICS Reports Q3 Revenue $8,000	Nov. 06	MT
Keros Therapeutics, Inc. Presents Preclinical Data from its KER-065 Program at the 28th International Annual Congress of the World Muscle Society	23-10-04	CI
Keros Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-07	CI
Keros Therapeutics Presents Clinical Trial and Preclinical Study Results from Its KER-050 Program and Preclinical Data from Its Alk2 Inhibitor Program At the 28Th Annual Congress of the European Hematology Association	23-06-09	CI
KEROS THERAPEUTICS, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q)	23-05-04	AQ
Keros Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-04	CI
Keros Therapeutics Q4 Loss Widens	23-03-03	MT
KEROS THERAPEUTICS, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-K)	23-03-03	AQ
Keros Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-03	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Keros Therapeutics, Inc.

Equities

KROS

US4923271013

Highlights

Filters